Pancreatic Cancer Research

ResearcherNorthwestern UniversityActive in the last 2 years

Zhiyong Liang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-4787-2925; OpenAlex author ID A5100727903, A5121592780, A5122195257. Sources: OpenAlex.

Their work

Papers
55 (first author 1, last author 21)
Trials
0
Grants
0
Labs led
1
Collaborators
94
Papers, trials and grants by year

2015: 4 papers · 2016: 5 papers · 2017: 5 papers · 2018: 7 papers · 2019: 5 papers · 2020: 6 papers · 2021: 7 papers · 2022: 4 papers · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 5 papers

Papers 50 of 55

  1. Tumor-Derived LAMB3 Drives Immunosuppressive LRRC15+ Fibroblast Formation During Pancreatic Ductal Adenocarcinoma Development. Last author DOI 10.1002/advs.202520029↗
  2. AI-driven tumor heterogeneity quantification and survival prediction in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41746-026-02979-7↗
  3. ALKBH5 in Cancer-Associated Fibroblasts Governs an Epitranscriptomic Axis That Drives Pancreatic Cancer Metastasis. Last author DOI 10.1158/0008-5472.can-25-2950↗
  4. Safety and oncologic efficacy of robotic surgery compared to open surgery after neoadjuvant therapy for pancreatic cancer. Co-author DOI 10.1186/s12893-026-03942-9↗
  5. LINC01963 promotes pancreatic ductal adenocarcinoma proliferation via METTL3/IGF2BP2 axis-mediated m⁶A modification of c-Myc. Last author DOI 10.1186/s13046-026-03650-5↗
  6. NFE2-driven neutrophil polarization promotes pancreatic cancer liver metastasis progression. Co-author DOI 10.1016/j.celrep.2024.115226↗
  7. Labor-Efficient Pathological Auxiliary Diagnostic Model for Primary and Metastatic Tumor Tissue Detection in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.modpat.2025.100764↗
  8. Erratum: Chinese expert consensus on imaging assessment of pancreatic ductal adenocarcinoma (PDAC) resectability. Co-author DOI 10.1097/jp9.0000000000000235↗
  9. WFDC3 identified as a prognostic and immune biomarker in pancreatic cancer. Last author DOI 10.17305/bb.2025.12444↗
  10. The Causal Association between Gut Microbiota and Pancreatic Cancer: A Two-sample Mendelian Randomization Analysis in European and East Asian Populations Last author DOI 10.1101/2024.04.23.24306212↗
  11. Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth. Last author DOI 10.1016/j.canlet.2022.216040↗
  12. A novel cuproptosis-related gene model predicts outcomes and treatment responses in pancreatic adenocarcinoma. Last author DOI 10.1186/s12885-023-10678-9↗
  13. Multi-omics analysis of intra-tumoural and inter-tumoural heterogeneity in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ctm2.670↗
  14. FGFR3 Nuclear Translocation Contributes to Proliferative Potential and Poor Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002056↗
  15. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA. Last author DOI 10.1186/s12916-022-02647-z↗
  16. Investigation of clinical application of claudin 18 isoform 2 in pancreatic ductal adenocarcinoma: A retrospective analysis of 302 chinese patients. Last author DOI 10.14670/hh-18-477↗
  17. Genetic aberrations in Chinese pancreatic cancer patients and their association with anatomic location and disease outcomes. Last author DOI 10.1002/cam4.3679↗
  18. A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients. Last author DOI 10.1016/j.prp.2020.153313↗
  19. Expression and Prognostic Value of Small Mothers Against Decapentaplegic 7, Matrix Metalloproteinase 2, and Matrix Metalloproteinase 9 in Resectable Pancreatic… Co-author DOI 10.1097/mpa.0000000000001892↗
  20. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients… Co-author DOI 10.1111/jgh.15244↗
  21. RNA m6A Demethylase ALKBH5 Protects Against Pancreatic Ductal Adenocarcinoma via Targeting Regulators of Iron Metabolism. Last author DOI 10.3389/fcell.2021.724282↗
  22. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy. Last author DOI 10.3389/fimmu.2021.690056↗
  23. Automatic Pancreatic Ductal Adenocarcinoma Detection in Whole Slide Images Using Deep Convolutional Neural Networks. Co-author DOI 10.3389/fonc.2021.665929↗
  24. Prognostic and predictive value of a five-molecule panel in resected pancreatic ductal adenocarcinoma: A multicentre study. Co-author DOI 10.1016/j.ebiom.2020.102767↗
  25. Ubiquitin-specific protease 4 predicts an unfavorable prognosis and promotes malignant behaviors in vitro in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2020.112317↗
  26. Matrix Metalloproteinase 11 as a Novel Tumor Promoter and Diagnostic and Prognostic Biomarker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001583↗
  27. Transducin-Like Enhancer of Split-1 Inhibits Malignant Behaviors in vitro and Predicts a Better Prognosis in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2020.00576↗
  28. Upregulation of exosomal microRNA‑21 in pancreatic stellate cells promotes pancreatic cancer cell migration and enhances Ras/ERK pathway activity. Co-author DOI 10.3892/ijo.2020.4986↗
  29. AREG mediates the epithelial‑mesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NF‑κB signalling pathway. Last author DOI 10.3892/or.2020.7523↗
  30. WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer. First author DOI 10.1016/j.canlet.2019.02.043↗
  31. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation. Last author DOI 10.1016/j.canlet.2019.07.015↗
  32. Clinicopathological and prognostic significance of MKK4 and MKK7 in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.humpath.2018.11.026↗
  33. PSME3 Promotes TGFB1 Secretion by Pancreatic Cancer Cells to Induce Pancreatic Stellate Cell Proliferation. Last author DOI 10.7150/jca.30235↗
  34. Upregulation of nucleoprotein AHNAK is associated with poor outcome of pancreatic ductal adenocarcinoma prognosis via mediating epithelial-mesenchymal transiti… Co-author DOI 10.7150/jca.31291↗
  35. Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207. Co-author DOI 10.1002/1878-0261.12393↗
  36. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.25253↗
  37. High expression of GRK3 is associated with favorable prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.prp.2017.11.013↗
  38. ZIP4 Promotes Pancreatic Cancer Progression by Repressing ZO-1 and Claudin-1 through a ZEB1-Dependent Transcriptional Mechanism. Co-author DOI 10.1158/1078-0432.ccr-18-0263↗
  39. PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay. Co-author DOI 10.1186/s13000-017-0678-4↗
  40. Retraction: PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation. Co-author DOI 10.18632/oncotarget.25033↗
  41. Plasminogen Activator Inhibitor 1 as a Poor Prognostic Indicator in Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.4103/0366-6999.247211↗
  42. Expression of key mTOR pathway components in pancreatic ductal adenocarcinoma: A multicenter study for clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.canlet.2017.02.036↗
  43. Asporin promotes pancreatic cancer cell invasion and migration by regulating the epithelial-to-mesenchymal transition (EMT) through both autocrine and paracrin… Co-author DOI 10.1016/j.canlet.2017.04.001↗
  44. Expression of signaling adaptor proteins predicts poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13000-017-0633-4↗
  45. PDZ-containing 1 acts as a suppressor of pancreatic cancer by regulating PTEN phosphorylation. Co-author DOI 10.18632/oncotarget.20552↗
  46. SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis. Co-author DOI 10.3892/ijo.2017.4111↗
  47. Expression and Significances of MTSS1 in Pancreatic Cancer. Co-author DOI 10.1007/s12253-015-9963-2↗
  48. G-protein-coupled receptor kinase 2 in pancreatic cancer: clinicopathologic and prognostic significance. Co-author DOI 10.1016/j.humpath.2016.06.012↗
  49. CT Imaging Biomarkers Predict Clinical Outcomes After Pancreatic Cancer Surgery. Co-author DOI 10.1097/md.0000000000002664↗
  50. Expression of amphiregulin predicts poor outcome in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13000-016-0512-4↗

Closest collaborators

The 25 strongest of 94 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Huanwen Wu · 25 shared papers, 2015–2026 · strength 3.27
  2. Xiaoding Liu · 12 shared papers, 2019–2026 · strength 2.10
  3. Lei You · 18 shared papers, 2015–2022 · strength 1.63
  4. Li Zhou · 17 shared papers, 2015–2022 · strength 1.57
  5. Junchao Guo · 13 shared papers, 2015–2025 · strength 1.39
  6. Junliang Lu · 10 shared papers, 2016–2026 · strength 1.28
  7. Jun Lü · 10 shared papers, 2017–2022 · strength 1.11
  8. Menghua Dai · 6 shared papers, 2020–2026 · strength 0.99
  9. Yu-Pei Zhao · 12 shared papers, 2015–2020 · strength 0.91
  10. Tonghua Liu · 10 shared papers, 2015–2020 · strength 0.88
  11. Zhiwen Zhang · 6 shared papers, 2018–2022 · strength 0.84
  12. Hangqi Liu · 4 shared papers, 2021–2026 · strength 0.76
  13. Xuqing Shi · 3 shared papers, 2025–2026 · strength 0.76
  14. Qixian Liu · 3 shared papers, 2023–2026 · strength 0.72
  15. Ruiyu Li · 4 shared papers, 2021–2023 · strength 0.71
  16. Bolun Jiang · 5 shared papers, 2020–2022 · strength 0.65
  17. Taiping Zhang · 8 shared papers, 2016–2020 · strength 0.63
  18. Huadan Xue · 4 shared papers, 2015–2026 · strength 0.62
  19. Qiaofei Liu · 4 shared papers, 2019–2025 · strength 0.60
  20. Bohan Liu · 2 shared papers, 2025–2026 · strength 0.54
  21. Wei‐Min Tong · 3 shared papers, 2021–2026 · strength 0.52
  22. Qiang Ma · 5 shared papers, 2017–2020 · strength 0.48
  23. Haitao Zhang · 2 shared papers, 2026 · strength 0.47
  24. Lianyuan Yu · 4 shared papers, 2019–2022 · strength 0.47
  25. Hui Zhang · 5 shared papers, 2015–2021 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.